A 83-01 [909910-43-6]

Catalog number: HY-10432_10mg
Brand: MedChem Express
Packing: 10 mg
Other sizes: Other sizes available
Price: € 144.00
Expected delivery time: 10 days

Product specifications for - A 83-01 [909910-43-6]

Product group: Chemicals
Category: Other
CAS No.: 909910-43-6
Purity: >98%
Molecular Formula: C25H19N5S
Molecular weight: 421.52
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Scientific information: 
Scientific info: A 83-01 is a selective inhibitor of TGF-beta type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values are 12, 45 and 7.5 nM respectively). IC50 Value: 12 nM ( ALK5) Target: ALK5 A 83-01 blocks phosphorylation of Smad2 and inhibits TGF-beta-induced epithelial-to-mesenchymal transition. A 83-01 only weakly inhibits ALK-1, -2, -3, -6 and MAPK activity and is more potent than SB 431542. in vitro: A-83-01, an inhibitor of TGF-beta type I receptor, increased the expression of Myf5 and MyoD, and enhanced myotube formation [1]. Microarray analysis of HM-1 cells treated with TGF-beta1 and/or A-83-01 revealed that A-83-01 efficiently inhibited transcriptional changes that are induced by TGF-beta1 [2]. -83-01 treatment significantly increased these parameters within 24 h that was positively related to pericyte coverage and tumor cell proliferation. Furthermore, apparent diffusion coefficient (ADC) determined by diffusion-weighed imaging was decreased by A-83-01 treatment, suggesting the decrease of tumor interstitial fluid pressure. Vascular function of the tumor improved by A-83-01treatment well assessed on post-Gd-L-enhanced MR images [3]. in vivo: The targeting efficacy of single intravenous injections of F-SL combined with A-83-01 was evaluated by measurement of the biodistribution and the antitumor effect in mice bearing murine lung carcinoma M109. A-83-01 temporarily changed the tumor vasculature around 3 h post injection. A-83-01 induced 1.7-fold higher drug accumulation of F-SL in the tumor than liposome alone at 24 h post injection [4].
Safety information: 
Additional information: 
Synonyms: HY-10432
Theranostics. 2021 Mar 14;11(11):5539-5552. Read more
Science. 2020 Dec 4;370(6521):eaay2002. Read more
Sci Adv. 2021 Apr 14;7(16):eabb2213. Read more
Methods Mol Biol. 2021 Jun 15. Read more
J Transl Med. 2021 Dec 7;19(1):497. Read more
Gynecol Oncol. 2019 Mar 27. pii: S0090-8258(19)30136-2. Read more
Gynecol Oncol. 2019 Jun;153(3):639-650. Read more
Front Med. 2021 Sep 23;8:746298. Read more
FASEB J. 2020 Aug;34(8):11185-11199. Read more
Research Square Preprint. 2021 Jan. Read more